
LQDA Stock Forecast & Price Target
LQDA Analyst Ratings
Bulls say
Liquidia is poised for success due to its innovative approach to addressing unmet patient needs, with a current focus on pulmonary hypertension. The company's proprietary PRINT technology allows for precise and uniform production of drug particles, giving it a competitive advantage in the biopharmaceutical industry. With a successful launch of its product YUTREPIA, strong revenue growth, and continued positive uptake, Liquidia is expected to achieve its target of over $1 billion in net revenue by 2027. While there are inherent risks in the biopharmaceutical market, including competition and potential financial needs, these are mitigated by the company's strong market position, increased prescribing breadth and depth, and positive sentiment from key opinion leaders. The recent Supreme Court ruling in the Amarin v. Hikma case, and its potential impact on the ongoing legal battle with United Therapeutics, could further solidify the company's position in the market. Overall, the positive trajectory of Liquidia's business and its potential for continued success make it a strong investment opportunity.
Bears say
Liquidia is facing multiple challenges, with the pending legal decision being the key overhang, which could significantly impact the company's position in the inhaled prostacyclin market. The recent Amarin v. Hikma ruling shows the potential for a severe outcome for Liquidia in the ongoing legal battle. Furthermore, the company faces competition from established players, such as United Therapeutics, and may require additional financing to complete its drug development.
This aggregate rating is based on analysts' research of Liquidia Technologies Inc and is not a guaranteed prediction by Public.com or investment advice.
LQDA Analyst Forecast & Price Prediction
Start investing in LQDA
Order type
Buy in
Order amount
Est. shares
0 shares